keyword
MENU ▼
Read by QxMD icon Read
search

ABVD

keyword
https://www.readbyqxmd.com/read/28912294/brentuximab-is-it-time-for-a-new-b-in-abvd
#1
Deborah M Stephens
No abstract text is available yet for this article.
September 14, 2017: Blood
https://www.readbyqxmd.com/read/28902084/children-and-adolescent-hodgkin-lymphoma-in-argentina-long-term-results-after-combined-abvd-and-restricted-radiotherapy
#2
Pedro A Zubizarreta, Elizabeth Alfaro, Myriam Guitter, Cristian Sanchez La Rosa, María L Galluzzo, Natalia Millán, Fernando Fiandrino, María S Felice
OBJECTIVE: Prospective analysis of clinical characteristics and long-term treatment results of a pediatric cohort with Hodgkin lymphoma (HL) treated in a single institution with ABVD and restricted radiotherapy (RT). PATIENTS AND METHODS: Between September 2000 and December 2015, 165 new consecutive assessable patients with HL were registered at our institution. Lymphocyte predominant nodular HL was excluded. Low risk (LR) patients were stage I and IIA (no bulky disease, <4 involved ganglionar areas and no lung hilar nodes), high risk (HR) was assigned to stage IV and any other stage with bulky mediastinum...
September 8, 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/28901021/optimisation-of-chemotherapy-and-radiotherapy-for-untreated-hodgkin-lymphoma-patients-with-respect-to-second-malignant-neoplasms-overall-and-progression-free-survival-individual-participant-data-analysis
#3
REVIEW
Jeremy Franklin, Dennis A Eichenauer, Ingrid Becker, Ina Monsef, Andreas Engert
BACKGROUND: Efficacy and the risk of severe late effects have to be well-balanced in treatment of Hodgkin lymphoma (HL). Late adverse effects include secondary malignancies which often have a poor prognosis. To synthesise evidence on the risk of secondary malignancies after current treatment approaches comprising chemotherapy and/or radiotherapy, we performed a meta-analysis based on individual patient data (IPD) from patients treated for newly diagnosed HL. OBJECTIVES: We investigated several questions concerning possible changes in the risk of secondary malignancies when modifying chemotherapy or radiotherapy (omission of radiotherapy, reduction of the radiation field, reduction of the radiation dose, use of fewer chemotherapy cycles, intensification of chemotherapy)...
September 13, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28898338/-response-to-abvd-chemotherapeutic-protocol-in-patients-with-early-stage-hodgkin%C3%A2-s-lymphoma
#4
Javier Díaz, Katherine Soto, Daniel Ernst
BACKGROUND: Recent trials show that > 90% of patients with early stage Hodgkin`s Lymphoma (ESHL) can be cured, especially when using the ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapeutic (CT) protocol. The use of radiotherapy (RT) is variable and can be selected according to the presence of specific risk factors, including PET-CT, as recently reported. AIM: To report the experience in the treatment of ESHL. MATERIAL AND METHODS: Retrospective and descriptive analysis of patients with ESHL treated at the Red de Salud UC-Christus between 2011-2015...
May 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/28832956/early-stage-hodgkin-lymphoma-outcomes-after-combined-modality-therapy-according-to-the-post-chemotherapy-5-point-score-can-residual-pet-positive-disease-be-cured-with-radiotherapy-alone
#5
Sarah A Milgrom, Chelsea C Pinnix, Hubert Chuang, Yasuhiro Oki, Mani Akhtari, Osama Mawlawi, Naveen Garg, Jillian R Gunther, Jay P Reddy, Grace L Smith, Eric Rohren, Frederick B Hagemeister, Hun J Lee, Luis E Fayad, Wenli Dong, Eleanor M Osborne, Zeinab Abou Yehia, Michelle Fanale, Bouthaina S Dabaja
Early-stage classical Hodgkin lymphoma (HL) patients are evaluated by an end-of-chemotherapy positron emission tomography-computed tomography (eoc-PET-CT) after doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) and before radiation therapy (RT). We determined freedom from progression (FFP) in patients treated with ABVD and RT according to the eoc-PET-CT 5-point score (5PS). Secondarily, we assessed whether patients with a positive eoc-PET-CT (5PS of 4-5) can be cured with RT alone. The cohort comprised 174 patients treated for stage I-II HL with ABVD and RT alone...
August 18, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28768235/infradiaphragmatic-hodgkin-lymphoma-a-large-series-of-patients-staged-with-pet-ct
#6
Cédric Rossi, Morgane Mounier, Pauline Brice, Violaine Safar, Emmanuelle Nicolas-Virelizier, Philippe Rey, Aspasia Stamatoullas-Bastard, Marion Alcantara, Adrien Chauchet, Emilie Reboursière, Lauriane Filliatre, Aurore Perrot, Sylvain Garciaz, Gilles Salles, Bertrand Coiffier, Hervé Ghesquières, René-Olivier Casasnovas
INTRODUCTION: Infradiaphragmatic Hodgkin Lymphoma (IDHL) accounts for 3-11% of adult cases of stage I-II Hodgkin Lymphoma and the treatment strategy in IDHL is still heterogeneous. All previous published studies were conducted before the PET-CT era. PET may provide a more accurate evaluation of IDHL stage. The aim of this study was to analyze the clinical and biological characteristics of IDHL patients staged by CT scan or PET-CT in eight French hematology departments and their impact on outcomes in these patients...
July 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28744882/epstein-barr-virus-positivity-is-associated-with-angiogenesis-in-and-poorer-survival-of-patients-receiving-standard-treatment-for-classical-hodgkin-s-lymphoma
#7
Young Wha Koh, Jae-Ho Han, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh
Epstein-Barr virus (EBV) is a significant contributor to the development of classical Hodgkin's lymphoma (cHL). Recent studies have documented associations between angiogenesis and EBV-associated malignancies. No study has yet examined the associations among, and prognostic implications of, EBV infection, vascular endothelial growth factor (VEGF) expression, and microvessel density (MVD) in cHL patients. Diagnostic tissues from 135 cHL patients treated with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) were retrospectively evaluated by in situ hybridization of EBV-encoded small RNA (EBER) and immunohistochemical staining for VEGF and CD31 (a measure of MVD)...
July 26, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28733323/five-year-follow-up-of-brentuximab-vedotin-combined-with-abvd-or-avd-for-advanced-stage-classical-hodgkin-lymphoma
#8
LETTER
Joseph M Connors, Stephen M Ansell, Michelle Fanale, Steven I Park, Anas Younes
No abstract text is available yet for this article.
September 14, 2017: Blood
https://www.readbyqxmd.com/read/28722111/monoamine-oxidase-a-is-highly-expressed-in-classical-hodgkin-lymphoma
#9
Pei Chuan Li, Imran N Siddiqi, Anja Mottok, Eric Y Loo, Chieh Hsi Wu, Wendy Cozen, Christian Steidl, Jean Chen Shih
Monoamine oxidase A (MAOA) is a mitochondrial enzyme that catalyzes oxidative deamination of neurotransmitters and dietary amines and produces H2 O2 . It facilitates the progression of gliomas and prostate cancer, but its expression and functional relevance have not been studied in lymphoma. Here, we evaluated MAOA in 427 cases of Hodgkin and non-Hodgkin lymphoma and in a spectrum of reactive lymphoid tissues by immunohistochemistry on formalin-fixed, paraffin-embedded specimens. MAOA was expressed by Hodgkin Reed-Sternberg (HRS) cells in the majority of classical Hodgkin lymphomas (cHLs) (181/241; 75%), with 34...
July 19, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28708228/clinical-and-subclinical-cardiac-late-effects-in-pediatric-hodgkin-s-lymphoma-survivors
#10
Carlo Materazzo, Maura Massimino, Elisabetta Schiavello, Marta Podda, Lorenza Gandola, Graziella Cefalo, Serena Catania, Cristina Meazza, Ivan Moschetti, Monica Terenziani
PURPOSE: Cardiac late effects are responsible for a significant burden of mortality and morbidity among pediatric Hodgkin's lymphoma (HL) survivors (HLS). The aim of our study was to assess clinical and subclinical cardiac sequelae in a cohort of childhood HLS treated in the 1980s with doxorubicin, bleomycin, vinblastine, and dacarbazine (the ABVD regimen) and limited-field radiotherapy (RT). METHODS: We retrospectively examined a series of HLS treated from 1979 to 1989...
July 8, 2017: Tumori
https://www.readbyqxmd.com/read/28660348/the-role-of-f-18-fdg-pet-ct-in-evaluating-the-impact-of-hiv-infection-on-tumor-burden-and-therapy-outcome-in-patients-with-hodgkin-lymphoma
#11
Ismaheel O Lawal, Nozipho E Nyakale, Lerwine M Harry, Moshe R Modiselle, Alfred O Ankrah, Alphonse P Msomi, Neo P Mokgoro, Tebatso G Boshomane, Christophe Van de Wiele, Mike M Sathekge
BACKGROUND: To evaluate the impact of HIV infection on tumor burden and therapy outcome following treatment with chemotherapy in patients with Hodgkin lymphoma. METHODS: A total of 136 patients with classical Hodgkin lymphoma were studied (mean age ± SD = 32.31 ± 1.39 years, male = 86, female = 50). Advanced disease (stage III and IV) was present in 64% of patients. HIV infection was present in 57 patients while 79 patients were HIV-negative. Baseline F-18 FDG PET/CT was obtained in all patients...
June 28, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28646013/doxorubicin-effect-on-myocardial-metabolism-as-a-pre-requisite-for-subsequent-development-of-cardiac-toxicity-a-translational-18-f-fdg-pet-ct-observation
#12
Matteo Bauckneht, Giulia Ferrarazzo, Francesco Fiz, Silvia Morbelli, Matteo Sarocchi, Fabio Pastorino, Alberto Ghidella, Elena Pomposelli, Maurizio Miglino, Pietro Ameri, Laura Emionite, Flavia Ticconi, Eleonora Arboscello, Ambra Buschiazzo, Elena Augusta Massimelli, Salvatore Fiordoro, Anna Borra, Vanessa Cossu, Annalisa Bozzano, Adalberto Ibatici, Mirco Ponzoni, Paolo Spallarossa, Andrea Gallamini, Paolo Bruzzi, Gianmario Sambuceti, Cecilia Marini
The present translational study aimed to verify whether serial (18)F-fluoro-deoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT), predicts doxorubicin cardiotoxicity. Methods: Fifteen athymic mice were treated with intravenous administration of saline (n = 5), doxorubicin 5 mg/Kg (n = 5) or doxorubicin 7.5 mg/Kg (n = 5) and submitted to dynamic microPET scan to estimate left ventricular glucose consumption (LV-MRGlu) before and after chemotherapy. Thereafter, we retrospectively identified 69 patients successfully treated with Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) regimen for Hodgkin's Disease (HD) and submitted to four consecutive FDG-PET/CT scans...
June 23, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28601705/abvd-or-beacoppbaseline-along-with-involved-field-radiotherapy-in-early-stage-hodgkin-lymphoma-with-risk-factors-results-of-the-european-organisation-for-research-and-treatment-of-cancer-eortc-groupe-d-%C3%A3-tude-des-lymphomes-de-l-adulte-gela-h9-u-intergroup-randomised
#13
RANDOMIZED CONTROLLED TRIAL
Christophe Fermé, José Thomas, Pauline Brice, Olivier Casasnovas, Andrej Vranovsky, Serge Bologna, Pieternella J Lugtenburg, Réda Bouabdallah, Patrice Carde, Catherine Sebban, Houchingue Eghbali, Gilles Salles, Gustaaf W van Imhoff, Antoine Thyss, Evert M Noordijk, Oumédaly Reman, Marnix L M Lybeert, Maud Janvier, Michele Spina, Bruno Audhuy, John M M Raemaekers, Richard Delarue, Bruno Anglaret, Okke de Weerdt, Zora Marjanovic, Robbert J H A Tersteeg, Daphne de Jong, Josette Brière, Michel Henry-Amar
PURPOSE: For early-stage Hodgkin lymphoma (HL), optimal chemotherapy regimen and the number of cycles to be delivered remain to settle down. The H9-U trial compared three modalities of chemotherapy followed by involved-field radiotherapy (IFRT) in patients with stage I-II HL and risk factors (NCT00005584). PATIENTS AND METHODS: Patients aged 15-70 years with untreated supradiaphragmatic HL with at least one risk factor (age ≥ 50, involvement of 4-5 nodal areas, mediastinum/thoracic ratio ≥ 0...
August 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28589704/modification-of-initial-therapy-in-early-and-advanced-hodgkin-lymphoma-based-on-interim-pet-ct-is-beneficial-a-prospective-multicentre-trial-of-355-patients
#14
Eldad J Dann, Osnat Bairey, Rachel Bar-Shalom, Tanya Mashiach, Elinor Barzilai, Abraham Kornberg, Luiza Akria, Tamar Tadmor, Kalman Filanovsky, Uri Abadi, Olga Kagna, Rosa Ruchlemer, Roxolyana Abdah-Bortnyak, Neta Goldschmidt, Ron Epelbaum, Netanel A Horowitz, David Lavie, Dina Ben-Yehuda, Ofer Shpilberg, Ora Paltiel
This multicentre study evaluated 5-year progression-free (PFS) and overall survival (OS) in early and advanced Hodgkin lymphoma (HL), where therapy was individualized based on initial prognostic factors and positron emission tomography-computed tomography performed after two cycles (PET-2). Between September 2006 and August 2013, 359 patients aged 18-60 years, were recruited in nine Israeli centres. Early-HL patients initially received ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) ×2. Depending on initial unfavourable prognostic features, PET-2-positive patients received additional ABVD followed by involved-site radiotherapy (ISRT)...
September 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28574963/hiv-infection-has-no-prognostic-impact-on-advanced-stage-hodgkin-lymphoma
#15
Marc Sorigué, Olga García, Gustavo Tapia, Maria-Joao Baptista, Miriam Moreno, José-Luis Mate, Juan M Sancho, Evarist Feliu, Josep-Maria Ribera, José-Tomás Navarro
OBJECTIVE: Classical Hodgkin lymphoma (cHL) is a non-AIDS-defining cancer with a good response to chemotherapy in the combined antiretroviral therapy (cART) era. The aim of the present study was to compare the characteristics, the response to treatment and the survival of advanced-stage cHL treated with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) between cART-treated HIV-positive and HIV-negative patients. DESIGN AND METHODS: We retrospectively analyzed advanced-stage cHL patients from a single institution, uniformly treated with ABVD...
June 19, 2017: AIDS
https://www.readbyqxmd.com/read/28541603/comparison-of-first-line-chemotherapy-including-escalated-beacopp-versus-chemotherapy-including-abvd-for-people-with-early-unfavourable-or-advanced-stage-hodgkin-lymphoma
#16
REVIEW
Nicole Skoetz, Andrea Will, Ina Monsef, Corinne Brillant, Andreas Engert, Bastian von Tresckow
BACKGROUND: There are two different international standards for the treatment of early unfavourable and advanced stage Hodgkin lymphoma (HL): chemotherapy with escalated BEACOPP (bleomycin/etoposide/doxorubicin/cyclophosphamide/vincristine/procarbazine/prednisone) regimen and chemotherapy with ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) regimen. OBJECTIVES: To determine the advantages and disadvantages of chemotherapy including escalated BEACOPP compared to chemotherapy including ABVD in the treatment of early unfavourable or advanced stage HL as first-line treatment...
May 25, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28504035/bleomycin-pulmonary-toxicity-does-not-adversely-affect-the-outcome-of-patients-with-hodgkin-lymphoma
#17
Haowei Linda Sun, Eshetu G Atenafu, Richard Tsang, Vishal Kukreti, Theodore K Marras, Michael Crump, John Kuruvilla
Bleomycin pulmonary toxicity (BPT) is a well-described complication of bleomycin-containing regimens. Previous data on risk factors and the impact of BPT on survival in Hodgkin lymphoma (HL) were conflicting. We reviewed 253 HL patients treated with adriamycin, bleomycin, vinblastine, dacarbazine (ABVD) at the Princess Margaret Hospital from 1999 to 2009 to examine the incidence and risk factors for BPT, and the effect of BPT on survival. BPT was defined by pulmonary symptoms, bilateral interstitial infiltrates on computed tomography, and the absence of infection...
May 15, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28484155/interdigitating-dendritic-cell-sarcoma-successfully-treated-with-abvd-therapy-in-which-serum-cea-levels-correlated-with-disease-activity
#18
Reona Sakemura, Junji Hiraga, Satoshi Kitagawa, Masafumi Ito, Tomohiro Kajiguchi, Shinichi Mizuno
Interdigitating dendritic cell sarcoma (IDCS) is an extremely rare neoplasm of spindle to ovoid cells with phenotypic features similar to those of interdigitating dendritic cells. No standard therapy for advanced IDCS has yet been established. According to past reports, CHOP-like regimens are often chosen as primary therapy. Herein, we report a case with advanced IDCS, for which ABVD achieved remarkable clinical improvement and serial CEA levels correlated with disease status. A 76-year-old man presented with general fatigue and pancytopenia with CEA elevation...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28418763/long-term-follow-up-of-contemporary-treatment-in-early-stage-hodgkin-lymphoma-updated-analyses-of-the-german-hodgkin-study-group-hd7-hd8-hd10-and-hd11-trials
#19
RANDOMIZED CONTROLLED TRIAL
Stephanie Sasse, Paul J Bröckelmann, Helen Goergen, Annette Plütschow, Horst Müller, Stefanie Kreissl, Carolin Buerkle, Sven Borchmann, Michael Fuchs, Peter Borchmann, Volker Diehl, Andreas Engert
Purpose Combined-modality treatment is widely considered the standard of care in early-stage Hodgkin lymphoma (HL), and treatment intensity has been reduced over the last years. Long-term follow-up is important to judge both efficacy and safety of the different therapies used. Patients and Methods We analyzed updated follow-up data on 4,276 patients treated within the German Hodgkin Study Group trials HD7 and HD10 for early-stage favorable HL and HD8 and HD11 for early-stage unfavorable HL between 1993 and 2003...
June 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28403692/severe-hypokalemia-due-to-a-possible-drug-drug-interaction-between-vinblastine-and-antiretrovirals-in-a-hiv-infected-patient-with-hodgkin-s-lymphoma
#20
Ezequiel Cordova, Laura Morganti, Andrea Odzak, Florencia Arcondo, Mariana Silva, Marcelo Zylberman, Claudia Rodriguez
A 60-year-old HIV-1 infected woman on antiretroviral therapy (emtricitabine/tenofovir, and ritonavir-boosted atazanavir) developed Hodgkin's lymphoma. The patient initiated ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) chemotherapy and presented with neutropenia and severe hypokalemia. Hypokalemia was considered as part of a proximal tubular renal dysfunction, and other causes of hypokalemia were excluded. Due to suspicion of drug--drug interactions between antiretrovirals and vinblastine, ritonavir-boosted atazanavir was switched to dolutegravir and the patient continued emtricitabine/tenofovir...
January 1, 2017: International Journal of STD & AIDS
keyword
keyword
71275
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"